A good performance from generics was driven by the successful recent launch of paclitaxel, as well as continued strong growth in Canada. Biosimilar net-sales growth would have been positive when ...

New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained ...

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago. The ...

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...